Dacomitinib

Type: Keyphrase

Name: Dacomitinib

First reported Jun 04 2013 - Updated Jun 04 2013 - 1 reports

Clovis Oncology Skyrockets After ASCO Presentations

One patient with a del19/T790M+ tumor had progressed on erlotinib immediately before beginning CO-1686 therapy. The patient, enrolled in the 300 mg BID cohort, is currently in cycle 6 of CO-1686 therapy, with a confirmed PROne patient with an L858R/T790M+ ... [Published BioMedReports - Jun 04 2013]

Entities: Clovis Oncology Inc, erlotinib, Tumor

Quotes

...said Lecia Sequist of the Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, Boston. "It has been exciting and quite hopeful to observe that patients are responding to CO-1686 and that the side effect profile has been so mild. A drug that works effectively for EGFR acquired resistance would be welcomed by the lung cancer community."

Clovis Oncology Reports Clinical Study of CO-1686 [Published Individual.com - Jun 06 2013]

"The DECISION results demonstrate sorafenib's ability to extend progression-free survival compared to placebo in these patients, potentially providing a new treatment option for these patients,” trial PI Marcia Brose, M D , Ph D , said in a statement. Roche’s Genetech said that addition of its Avastin® (bevacizumab) to chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) extended the lives of patients with advanced cervical cancer, compared to chemotherapy alone, in its Phase III GOG240 study. The firm found the Avastin-chemo combination reduced the risk of death by 29%, extending medial overall survival to 17 months, up from 13.3 months with chemotherapy alone."

Merck, BMS Immunotherapy Data Wets Clinical Oncology Appetite; More from ASCO [Published Genetic Engineering News - Jun 03 2013]

"The oncology community has been working to develop successful treatments for EGFR mutant patients with acquired resistance to erlotinib or gefitinib for several years without significant progress,” said Dr. Lecia V Sequist of the Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, Boston. “It has been exciting and quite hopeful to observe that patients are responding to CO-1686 and that the side effect profile has been so mild. A drug that works effectively for EGFR acquired resistance would be welcomed by the lung cancer community."

Clovis Oncology's Rucaparib Shows Encouraging Results from Ongoing Phase I/II Study [Published Benzinga.com - Jun 03 2013]

More From BioPortfolio on "Clovis Oncology’s CO-1686 Demonstrates Encouraging Results from Ongoing Phase I II Study in EGFR-mutant Non-Small Cell Lung Cancer"

Clovis Oncology’s CO-1686 Demonstrates Encouraging Results from Ongoing Phase I/II Study in EGFR- ... [Published BioPortfolio - Jun 03 2013]

More Content

sort by: Date \| Relevance
Clovis Oncology Reports Clinical Study of CO-1686 [Published Individual.com - Jun 06 2013]
Clovis Onocology Skyrockets After ASCO Presenta... [Published Proactive Investors USA - Jun 04 2013]
Clovis Oncology Skyrockets After ASCO Presentat... [Published BioMedReports - Jun 04 2013]
Merck, BMS Immunotherapy Data Wets Clinical Onc... [Published Genetic Engineering News - Jun 03 2013]
Clovis Oncology's Rucaparib Shows Encouraging R... [Published Benzinga.com - Jun 03 2013]
Clovis Oncology’s CO-1686 Demonstrates Encourag... [Published BioPortfolio - Jun 03 2013]
Pfizer and SFJ partner on Phase III trial of lu... [Published BioPortfolio - Sep 11 2012]
SFJ Pfizer partner to codevelop lung cancer drug [Published BioPortfolio - Sep 10 2012]
SFJ Pharma inks pact with Pfizer to co-develop ... [Published PharmaBiz - Sep 10 2012]